SXTP Stock Forecast: 60 Degrees Pharmaceuticals, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for 60 Degrees Pharmaceuticals, Inc. is $3.7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 36 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores 60 Degrees Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (75): Analysts have, on balance, been raising their forecasts.
Momentum (5): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
SXTP stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SXTP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 May 2026 | Ascendiant Capital | Maintains | Buy | $4.20 → $3.70 |
| 20 May 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 9 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 27 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Nov 2025 | Ascendiant Capital | Maintains | Buy | — |
| 14 Nov 2025 | HC Wainwright & Co. | Assumes | Buy | $6.00 |
| 3 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 2 June 2025 | Ascendiant Capital | Maintains | Buy | — |
| 28 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 25 Feb 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 10 Jan 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 23 Dec 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 11 Dec 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 13 Sept 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 6 June 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 3 Apr 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 20 Oct 2023 | HC Wainwright & Co. | Initiates | Neutral | — |
| 2 Oct 2023 | Ascendiant Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SXTP.
This page is one stock. Monday covers all of them.
SXTP appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
SXTP vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, 60 Degrees Pharmaceuticals, Inc. returned −88.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
SXTP analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 2.3×
- Price / book
- 0.5×
- EV / EBITDA
- —
Cheaper than 45% of US stocks
Cheaper than 86% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 27.3%
- Operating margin
- —
- Net margin
- —
Higher than 30% of US stocks
- Return on equity
- −327.4%
- Return on assets
- −112.6%
- Dividend yield
- —
Higher than 4% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
60 Degrees Pharmaceuticals, Inc. has a market value of $2.1M and an enterprise value of $10.4M.
Revenue in the twelve months to 30 June 2026: $1.1M. The latest quarter grew 106.0% year on year.
Net income over the same four quarters: −$8.1M, a −730.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$9.1M, after $81K of capital spending.
60 Degrees Pharmaceuticals, Inc. employs 3 people — $370K of revenue per employee.
Data provided by Twelve Data
SXTP and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at SXTP’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own 60 Degrees Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about SXTP
What is the SXTP stock price forecast for 2026-2027?
The median 12-month analyst price target for 60 Degrees Pharmaceuticals, Inc. is $3.7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SXTP stock a buy right now?
Of the 2 analysts covering 60 Degrees Pharmaceuticals, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 60 Degrees Pharmaceuticals, Inc. 36 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SXTP?
As at 21 Nov 2026, 60 Degrees Pharmaceuticals, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (75 of 100).
Will SXTP stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $3.7, and Ticker Nerd's factor model ranks 60 Degrees Pharmaceuticals, Inc. 36 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SXTP stock forecast for 2030?
No analyst covering 60 Degrees Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SXTP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.7 to $3.7 over the next 12 months.
How has SXTP stock performed over the past year?
60 Degrees Pharmaceuticals, Inc. returned -88.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does 60 Degrees Pharmaceuticals, Inc. do?
60 Degrees Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for the prevention and treatment of infectious diseases. Its commercial portfolio centers on Arakoda, a malaria prevention therapy, while its broader pipeline includes tafenoquine-based programs and other candidates being studied for vector-borne, fungal, and viral infections.
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for the prevention and treatment of infectious diseases. Its commercial portfolio centers on Arakoda, a malaria prevention therapy, while its broader pipeline includes tafenoquine-based programs and other candidates being studied for vector-borne, fungal, and viral infections. The company works across areas such as malaria, babesiosis, respiratory infections, and dengue, reflecting a research strategy aimed at diseases with significant unmet medical need. 60 Degrees Pharmaceuticals Inc. serves as a niche biotechnology player in the healthcare market, combining product commercialization with ongoing clinical development. Headquartered in Washington, D.C., the company also maintains operations linked to research and collaboration in Australia.
CEO Dr. Geoffrey Stuart Dow Ph.D. · 3 employees · United States · https://www.60degreespharma.com